Humanin is, like MOTS-c in Batch 1, a mitochondrial-derived peptide — a
scientifically interesting class with a research base that is still mostly
preclinical.
Chemical identity & structure.
Humanin is a small peptide — commonly described as 24 amino acids — encoded
within the mitochondrial genome, in the 16S rRNA region. It was one of the first
mitochondrial-derived peptides identified, originally discovered in research on
cytoprotection in the context of neurodegeneration.
Mechanism of action.
Humanin is described in the literature as cytoprotective — protecting cells from
various forms of stress-induced death. Reported mechanisms include interaction
with apoptosis-regulating proteins and signaling through certain receptor
complexes, as well as effects on inflammatory and metabolic signaling. These
mechanisms are reported from preclinical research and should be read as
incompletely characterized.
Key research findings.
Preclinical research has reported protective effects in models of
neurodegeneration, metabolic stress, and age-related decline. Circulating
humanin levels have been studied in humans as a biomarker associated with aging
and metabolic state.
The research / citation base.
The humanin literature is predominantly preclinical, with human data largely
observational (biomarker associations) rather than interventional. There are no
large human trials of humanin administration; it is not an approved drug.
Its human safety and efficacy profile is unestablished.
No human clinical trial has established administration parameters for humanin; VialTalk does
not provide community-sourced dosing.
Quality & sourcing notes.
A batch-specific COA with mass-spectrometry identity and HPLC purity is the
minimum bar; analog forms of humanin exist in the research literature, so
confirm exactly which sequence a product contains.
*Research-use note: Educational summary of published research. Humanin is not an
approved drug; this is research context only and not medical advice.*
